Skip to content

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Savitree Maoleekoonpiroj, Michael Smylie, Renato G. Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, Pedro Santabarbara, Lesley Seymour

New England Journal of Medicine · 2005 · 5,451 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Shepherd, F. A., Pereira, J. R., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R. G., Kooten, M. V., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G. M., Santabarbara, P., & Seymour, L. (2005). Erlotinib in previously treated Non–Small-Cell lung cancer. New England Journal of Medicine, 353(2), 123–132. https://doi.org/10.1056/nejmoa050753

In text: (Shepherd et al., 2005)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy. METHODS: Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens. The patients were stratified according to center, performance status, response to prior chemotherapy, number of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo. RESULTS: The median age of the 731 patients who underwent randomization was 61.4 years; 49 percent had received two prior chemotherapy regimens, and 93 percent had received platinum-based chemotherapy. The response rate was 8.9 percent in the erlotinib group and less than 1 percent in the placebo group (P<0.001); the median duration of the response was 7.9 months and 3.7 months, respectively. Progression-free survival was 2.2 months and 1.8 months, respectively (hazard ratio, 0.61, adjusted for stratification categories; P<0.001). Overall survival was 6.7 months and 4.7 months, respectively (hazard ratio, 0.70; P<0.001), in favor of erlotinib. Five percent of patients discontinued erlotinib because of toxic effects. CONCLUSIONS: Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.

  1. Cancer statistics, 20222022
  2. Cancer Statistics, 20212021
  3. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening2011
  4. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer2016
  5. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer2015

Metadata from OpenAlex (CC0). Citations are generated from the published record.